Through the deal, American Medical Systems has a four year option to obtain distribution and license rights to Tissue Genesis’ regenerative cell technology including the Tissue Genesis Cell Isolation System for use in human pelvic health applications, with an additional two year right of first refusal.
Along with the payments, Tissue Genesis will receive rights to certain data and derivative technology developed under the agreement. Tissue Genesis, in turn, will provide American Medical Systems with instruments, disposables, and know-how to allow American Medical Systems to develop regenerative cell applications.
Through this new collaboration, American Medical Systems joins the Tissue Genesis Commercialization ConsortiumSM of companies, institutions and researchers who share their expertise.
Stuart Williams, chief science officer of Tissue Genesis, and a pioneer of adipose-derived cell technology, said: “The addition of American Medical Systems to the companies and institutions working on Tissue Genesis’ regenerative cell technology will extend our advancement in this market. This collaboration has the potential to propel both companies into the regenerative healthcare.”
Anton Krucky, president and CEO of Tissue Genesis, said: “We are proud to partner with American Medical Systems a company with true vision and initiative as they recognize the potential benefits of cell therapy. Adipose tissue is a rich source of regenerative cells including adult stem cells and these cells have shown promising results in their ability to help patients.”